Oral PCSK9 Inhibitors as an Emerging Frontier in Lipid Management: A Meta-Analysis

Background Proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) are effective lipid-lowering therapies that reduce cardiovascular risk in hypercholesterolemia. Recent advances include oral PCSK9i, which may offer advantages over injectables. Purpose We aimed to assess the efficacy an…